Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SPRIT: SeQuent SCB vs RESTORE DEB for Recurrent Coronary In-Stent Restenosis
NCT07920055Not yet recruiting
- Sponsor
- Sir Run-Run Shaw Hospital
- Start
- Nov 2026
- Primary completion
- Aug 2028
- Countries
- 1
01
Overview
Randomised, open-label trial of sirolimus in coronary in-stent restenosis (ISR) (2 arms), sponsored by Sir Run-Run Shaw Hospital. Primary endpoint: In-Segment Late Lumen Loss at 9 Months. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
sirolimus
03
Conditions
coronary in-stent restenosis (ISR)
Beyond the preview
Go deeper on NCT07920055.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07920055.